Tharimmune Inc. (THAR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tharimmune Inc. (THAR) has a cash flow conversion efficiency ratio of -0.026x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.44 Million) by net assets ($397.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Tharimmune Inc.'s balance sheet to measure how much of total assets are equity-financed.
Tharimmune Inc. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Tharimmune Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Tharimmune Inc. (THAR) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Tharimmune Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tharimmune Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BEC World Public Company Limited
BK:BEC
|
0.049x |
|
TH Plantations Bhd
KLSE:5112
|
0.028x |
|
Horizon Gold Ltd
AU:HRN
|
-0.016x |
|
Antony Waste Handling Cell Limited
NSE:AWHCL
|
0.035x |
|
Betmakers Technology Group Ltd
AU:BET
|
0.053x |
|
GAMCO Natural Resources Gold and Income Closed Fund
NYSE:GNT
|
N/A |
|
Hariom Pipe Industries Limited
NSE:HARIOMPIPE
|
0.063x |
|
Bastogi S.p.A
F:BAOA
|
0.002x |
Annual Cash Flow Conversion Efficiency for Tharimmune Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of Tharimmune Inc. from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Tharimmune Inc. worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $397.93 Million | $-16.13 Million | -0.041x | +99.51% |
| 2024-12-31 | $1.31 Million | $-10.90 Million | -8.337x | -942.85% |
| 2023-12-31 | $9.13 Million | $-7.30 Million | -0.799x | +32.42% |
| 2022-12-31 | $5.54 Million | $-6.56 Million | -1.183x | -610.21% |
| 2021-12-31 | $-4.68 Million | $-1.09 Million | 0.232x | -20.07% |
| 2020-12-31 | $-3.72 Million | $-1.08 Million | 0.290x | -33.35% |
| 2019-12-31 | $-1.62 Million | $-706.11K | 0.435x | -- |
About Tharimmune Inc.
Tharimmune, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. It is also involved in the clinical-stage biotech research and development activities. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. w… Read more